Drug Trial Radar · NCT06548542
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
590
Planned (sponsor's estimate)
Start
Sep 4, 2024
Primary completion
Jan 2030
Study completion Jan 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD. The medicines assessed in this study are risankizumab, trosunilimab, lutikizumab, and ABBV-8736. When participants join the study, they will be randomized into available study treatment groups. Adult participants with CD will be enrolled. Around 590 participants will be enrolled in the study at approximately 300 sites worldwide. Risankizumab and trosunilimab are given as an injection under the skin or as an infusion into the vein. Lutikizumab is given as an injection under the skin. ABBV-8736 is given as an infusion into the vein. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, endoscopies, checking for side effects and completing questionnaires and a daily diary.
Conditions
- Crohn's Disease
Interventions
RisankizumabDrug
Subcutaneous Injection
LutikizumabDrug
Subcutaneous Injection
TrosunilimabDrug
Intravenous Infusion
RisankizumabDrug
Intravenous Infusion
TrosunilimabDrug
Subcutaneous Injection
ABBV-8736Drug
Intravenous Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants who Achieve Endoscopic RemissionTime frame: Week 12
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 96 weeks
Locations
255 sites in 33 countries. Site status is shown where the registry gives one.
Digestive Health Specialists /ID# 266216
Dothan, Alabama · Recruiting
East View Medical Research /ID# 270377
Mobile, Alabama · Recruiting
Southern California Res. Ctr /ID# 265549
Coronado, California · Recruiting
UC San Diego Health System /ID# 265565
La Jolla, California · Recruiting
uc davis medical center - patient support services building /ID# 265554
Sacramento, California · Recruiting
Clinical Applications Laboratories - San Diego - 3rd Avenue /ID# 267391
San Diego, California · Completed
Peak Gastroenterology Associates - Colorado Springs - North Cascade Avenue /ID# 265557
Colorado Springs, Colorado · Recruiting
Danbury Hospital, Western Connecticut Health Network /ID# 265556
Danbury, Connecticut · Recruiting
Yale University School of Medicine /ID# 266786
New Haven, Connecticut · Recruiting
Novum Research /ID# 278128
Clermont, Florida · Recruiting
University of Florida College of Medicine /ID# 266930
Gainesville, Florida · Recruiting
Nature Coast Clinical Research - Inverness /ID# 265874
Inverness, Florida · Recruiting
Atlantic Medical Research /ID# 266207
Margate, Florida · Recruiting
A Plus Research /ID# 265878
Miami, Florida · Recruiting
Sanchez Clinical Research /ID# 265887
Miami, Florida · Recruiting
Advanced Research Institute, Inc /ID# 265548
New Port Richey, Florida · Recruiting
Hillcrest Medical Research, LLC /ID# 267237
Orange City, Florida · Recruiting
Endoscopic Research, Inc. /ID# 267211
Orlando, Florida · Recruiting
Gcp Clinical Research /ID# 278126
Tampa, Florida · Recruiting
AdventHealth Medical Group - Tampa - Bruce B Downs Boulevard /ID# 265538
Tampa, Florida · Recruiting
Florida Medical Clinic - Zephyrhills /ID# 267392
Zephyrhills, Florida · Recruiting
Gastroenterology Associates of Central Georgia /ID# 265547
Macon, Georgia · Recruiting
Treasure Valley Medical Research /ID# 267114
Boise, Idaho · Recruiting
University of Chicago Medical Center /ID# 267400
Chicago, Illinois · Recruiting
OSF St. Francis Medical Center /ID# 266973
Peoria, Illinois · Recruiting
Springfield Clinic Main Campus /ID# 267434
Springfield, Illinois · Recruiting
Indiana University Health University Hospital /ID# 278129
Indianapolis, Indiana · Recruiting
University of Kentucky Chandler Medical Center /ID# 265564
Lexington, Kentucky · Recruiting
Metropolitan Gastroenterology Group - Chevy Chase /ID# 265877
Chevy Chase, Maryland · Recruiting
Velocity Clinical Research - Rockville /ID# 267712
Rockville, Maryland · Completed
Lucida Clinical Trials /ID# 266548
New Bedford, Massachusetts · Recruiting
Henry Ford Medical Center - Columbus /ID# 266503
Novi, Michigan · Recruiting
Mayo Clinic-Rochester /ID# 265550
Rochester, Minnesota · Recruiting
GI Associates Research, LLC /ID# 267433
Columbia, Missouri · Recruiting
Bvl Research /ID# 265870
Liberty, Missouri · Recruiting
Washington University /ID# 266938
St Louis, Missouri · Recruiting
Vector Clinical Trials /ID# 265561
Las Vegas, Nevada · Recruiting
Nyu Langone Long Island Clinical Research Associates - Lake Success /ID# 265566
Lake Success, New York · Recruiting
Icahn School of Medicine at Mount Sinai /ID# 266857
New York, New York · Completed
Northwell Health-Lenox Hill Hospital /ID# 265527
New York, New York · Recruiting
Showing 40 of 255 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.